GlassScriptPhysician profile
Clayton H Bryan
NPI 1982654505
$3,510.44
in general payments reported to CMS, 2019-2025
28 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $225 · 2021: $699 · 2022: $391 · 2023: $607 · 2024: $665 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $528.96 | 2019-2025 | Simbrinza, Clareon, Rocklatan |
| Allergan, INC. | $458.03 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $297.18 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $288.94 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $243.80 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $217.44 | 2020-2025 | Acthar |
| Harrow Eye, LLC | $213.81 | 2024-2025 | Iheezo, Triesence, Vevye |
| Oyster Point Pharma, INC. | $157.11 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $144.15 | 2021-2025 | Idosetr, Istent Infinite |
| Tarsus Pharmaceuticals, INC. | $124.62 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $122.59 | 2019-2021 | |
| Ocular Therapeutix, INC. | $95.87 | 2021-2024 | Dextenza |
| Travere Therapeutics, INC. | $71.43 | 2021 | |
| Horizon Therapeutics Plc | $66.31 | 2022-2023 | Tepezza |
| Dompe US, INC. | $61.16 | 2024-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.89 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $43.40 | 2022-2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Omeros Corporation | $39.08 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $38.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.28 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $34.82 | 2022-2023 | Syfovre |
| Biotissue Holdings INC. | $34.04 | 2021-2022 | |
| Sandoz INC. | $29.00 | 2024 | Cimerli |
| Ani Pharmaceuticals, INC. | $23.35 | 2022 | |
| Eyepoint US, INC. | $22.87 | 2021 | |
| Alimera Sciences, INC. | $22.77 | 2021 | |
| Genentech USA, INC. | $21.53 | 2024 | Vabysmo |
| Coherus Oncology, INC. | $21.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.